Analyst Reco. Vaxart, Inc.

Equities

VXRT

US92243A2006

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-28 pm EDT			5-day change	1st Jan Change
0.8292 ^USD	-4.29%		-7.53%	+44.76%

May. 13	Transcript : Vaxart, Inc., Q1 2024 Earnings Call, May 13, 2024
May. 13	Vaxart, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

B. Riley Upgrades Vaxart to Buy From Neutral, Lifts PT to $2 From $1.50	Jan. 31	MT
Cantor Fitzgerald Adjusts Price Target on Vaxart to $4 From $6, Maintains Overweight Rating	23-08-07	MT
B. Riley Lowers Vaxart's PT to $1.50 From $6, Reflecting More Conservative Estimate of Ramp-up of Norovirus; Keeps Neutral Rating	22-12-19	MT
Cantor Fitzgerald Adjusts Vaxart's Price Target to $8 From $11, Reiterates Overweight Rating	22-09-02	MT
B. Riley Trims Vaxart's Price Target to $6 from $7 to Reflect Modest Increased Long Term Cost of Capital Amid Current Macro Conditions; Keeps Neutral Rating	22-05-19	MT
B. Riley Lowers Vaxart's Price Target to $7 from $9 to Reflect Long Term Higher Cost of Capital Amid Current Macro Conditions, Keeps Neutral Rating	22-03-07	MT
Jefferies Analyst Starts Vaxart at Buy, Adjusts Price Target to $12 From $13	21-12-29	MT
Cantor Fitzgerald Starts Vaxart at Overweight With $15 Price Target	21-11-02	MT
VAXART : B. Riley Downgrades Vaxart to Neutral from Buy, Lowers PT to $9 from $13 on 'Underwhelming' Immunogenicity Dataset, Challenging Near-term Catalyst Setup	21-06-30	MT
VAXART : Jefferies Initiates Coverage on Vaxart With Buy Rating, $13 Price Target	21-06-24	MT
Vaxart : Shares Jump After Piper Sandler Starts Coverage With Overweight Rating	21-06-11	MT
VAXART : Piper Sandler Starts Vaxart at Overweight With $18 Price Target	21-06-11	MT
VAXART : B. Riley Lowers Vaxart's Price Target to $13 from $16, Keeps Buy Rating	21-03-04	MT
VAXART : B. Riley Adjusts Vaxart PT to $16 From $22, Maintains Buy Rating	20-11-18	MT
Vaxart, Inc. Announces its Oral Flu Vaccine Significantly Reduced Rate of Influenza Infection in Phase 2 Challenge Study	18-01-31	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Discover our Free Content to Help You Better Understand the Stock Market.

100% Free Registration

fermer